Mahwah, New Jersey | August 19, 2025 – Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial).
This product is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine® for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. (NDA – 021506).
Distribution will begin in September 2025.
Market Overview
According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection market achieved *annual sales of approximately $60.7 million.
Leadership Comment
Marc Kikuchi, President & Business Head, North America, said:
“We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need.”
Important Notes
- Glenmark’s Micafungin for Injection USP is approved only for the indication(s) listed in Glenmark’s approved label.
- All brand names and trademarks are the property of their respective owners.
- Market includes brand and all available therapeutic equivalents. IQVIA® data is available for all approved RLD indications. Glenmark’s product is approved only for the indications listed in its approved label.
*Source: IQVIA® National Sales Perspectives: Retail & Non-Retail, June 2025
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a research‐led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments, focusing on therapeutic areas of respiratory, dermatology, and oncology.
- 11 world-class manufacturing facilities across 4 continents
- Operations in 80+ countries
- Featured in In Vivo/Scrip 100 (Top 100 Companies Ranked by R&D and Sales, 2022)
- Ranked in Generics Bulletin/In Vivo (Top 50 Generics & Biosimilars Companies by Sales, 2022)
- SBTi-approved GHG emission reduction targets (2023) – second Indian pharma company to achieve this
- CSR initiatives have impacted 3+ million lives in the last decade
🌐 More info: www.glenmarkpharma.com
📱 Follow Glenmark on LinkedIn (Glenmark Pharmaceuticals) and Instagram (@glenmark_pharma)
Media Contacts
📩 Aakanksha Pilay | corpcomm@glenmarkpharma.com | +91 7218171062
📩 Adfactors PR | glenmark@adfactorspr.com | +91 88502 91322
